nodes	percent_of_prediction	percent_of_DWPC	metapath
Olanzapine—ADRA1B—polycystic ovary syndrome	0.418	0.598	CbGaD
Olanzapine—ADRA1A—polycystic ovary syndrome	0.281	0.402	CbGaD
Olanzapine—FMO3—urine—polycystic ovary syndrome	0.00529	0.0854	CbGeAlD
Olanzapine—CYP2C19—urine—polycystic ovary syndrome	0.00234	0.0378	CbGeAlD
Olanzapine—CYP1A2—urine—polycystic ovary syndrome	0.00191	0.0308	CbGeAlD
Olanzapine—CYP2C9—urine—polycystic ovary syndrome	0.00181	0.0293	CbGeAlD
Olanzapine—HTR2A—urine—polycystic ovary syndrome	0.00149	0.0241	CbGeAlD
Olanzapine—FMO3—adrenal cortex—polycystic ovary syndrome	0.0014	0.0226	CbGeAlD
Olanzapine—CYP3A4—urine—polycystic ovary syndrome	0.00138	0.0223	CbGeAlD
Olanzapine—CYP2D6—urine—polycystic ovary syndrome	0.00136	0.022	CbGeAlD
Olanzapine—H1F0—embryo—polycystic ovary syndrome	0.00125	0.0203	CbGeAlD
Olanzapine—HTR1E—female gonad—polycystic ovary syndrome	0.00117	0.0189	CbGeAlD
Olanzapine—FMO3—pituitary gland—polycystic ovary syndrome	0.00113	0.0183	CbGeAlD
Olanzapine—FMO3—adipose tissue—polycystic ovary syndrome	0.00113	0.0182	CbGeAlD
Olanzapine—H1F0—adrenal cortex—polycystic ovary syndrome	0.00103	0.0166	CbGeAlD
Olanzapine—FMO3—adrenal gland—polycystic ovary syndrome	0.00101	0.0163	CbGeAlD
Olanzapine—FMO3—vagina—polycystic ovary syndrome	0.000938	0.0151	CbGeAlD
Olanzapine—H1F0—endometrium—polycystic ovary syndrome	0.000918	0.0148	CbGeAlD
Olanzapine—HRH2—adrenal gland—polycystic ovary syndrome	0.0009	0.0145	CbGeAlD
Olanzapine—DRD5—female gonad—polycystic ovary syndrome	0.000894	0.0144	CbGeAlD
Olanzapine—FMO3—endocrine gland—polycystic ovary syndrome	0.000877	0.0142	CbGeAlD
Olanzapine—H1F0—uterus—polycystic ovary syndrome	0.000846	0.0137	CbGeAlD
Olanzapine—DRD5—endocrine gland—polycystic ovary syndrome	0.000831	0.0134	CbGeAlD
Olanzapine—H1F0—pituitary gland—polycystic ovary syndrome	0.000831	0.0134	CbGeAlD
Olanzapine—H1F0—adipose tissue—polycystic ovary syndrome	0.000827	0.0134	CbGeAlD
Olanzapine—ORM1—endometrium—polycystic ovary syndrome	0.000783	0.0126	CbGeAlD
Olanzapine—HRH2—endocrine gland—polycystic ovary syndrome	0.000781	0.0126	CbGeAlD
Olanzapine—Quetiapine—ADRA1D—polycystic ovary syndrome	0.000769	0.163	CrCbGaD
Olanzapine—H1F0—adrenal gland—polycystic ovary syndrome	0.000742	0.012	CbGeAlD
Olanzapine—HTR2B—adrenal cortex—polycystic ovary syndrome	0.000741	0.012	CbGeAlD
Olanzapine—H1F0—female gonad—polycystic ovary syndrome	0.000692	0.0112	CbGeAlD
Olanzapine—H1F0—vagina—polycystic ovary syndrome	0.000688	0.0111	CbGeAlD
Olanzapine—Loxapine—ADRA1B—polycystic ovary syndrome	0.000672	0.143	CrCbGaD
Olanzapine—HTR2B—endometrium—polycystic ovary syndrome	0.000661	0.0107	CbGeAlD
Olanzapine—Quetiapine—ADRA1B—polycystic ovary syndrome	0.000656	0.139	CrCbGaD
Olanzapine—H1F0—endocrine gland—polycystic ovary syndrome	0.000643	0.0104	CbGeAlD
Olanzapine—HTR2B—uterus—polycystic ovary syndrome	0.000609	0.00984	CbGeAlD
Olanzapine—HTR2B—adipose tissue—polycystic ovary syndrome	0.000596	0.00962	CbGeAlD
Olanzapine—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.000583	0.00941	CbGeAlD
Olanzapine—Amoxapine—ADRA1A—polycystic ovary syndrome	0.000579	0.123	CrCbGaD
Olanzapine—Clozapine—ADRA1B—polycystic ovary syndrome	0.000564	0.12	CrCbGaD
Olanzapine—ALB—adrenal gland—polycystic ovary syndrome	0.000555	0.00897	CbGeAlD
Olanzapine—ORM1—endocrine gland—polycystic ovary syndrome	0.000549	0.00887	CbGeAlD
Olanzapine—CHRM3—adipose tissue—polycystic ovary syndrome	0.000536	0.00866	CbGeAlD
Olanzapine—HTR2B—adrenal gland—polycystic ovary syndrome	0.000535	0.00863	CbGeAlD
Olanzapine—ADRA2C—endometrium—polycystic ovary syndrome	0.000521	0.00841	CbGeAlD
Olanzapine—HTR1B—endocrine gland—polycystic ovary syndrome	0.000515	0.00831	CbGeAlD
Olanzapine—CHRM2—endocrine gland—polycystic ovary syndrome	0.000512	0.00827	CbGeAlD
Olanzapine—HTR2B—vagina—polycystic ovary syndrome	0.000495	0.008	CbGeAlD
Olanzapine—ADRA1A—adipose tissue—polycystic ovary syndrome	0.000492	0.00795	CbGeAlD
Olanzapine—DRD2—pituitary gland—polycystic ovary syndrome	0.000485	0.00782	CbGeAlD
Olanzapine—HTR2A—embryo—polycystic ovary syndrome	0.000483	0.00779	CbGeAlD
Olanzapine—ADRA2C—uterus—polycystic ovary syndrome	0.00048	0.00775	CbGeAlD
Olanzapine—HTR1A—adrenal gland—polycystic ovary syndrome	0.000479	0.00774	CbGeAlD
Olanzapine—ADRA2C—pituitary gland—polycystic ovary syndrome	0.000471	0.00761	CbGeAlD
Olanzapine—ADRA2C—adipose tissue—polycystic ovary syndrome	0.000469	0.00758	CbGeAlD
Olanzapine—CHRM1—endocrine gland—polycystic ovary syndrome	0.000466	0.00753	CbGeAlD
Olanzapine—HTR7—adrenal gland—polycystic ovary syndrome	0.000458	0.00739	CbGeAlD
Olanzapine—Loxapine—ADRA1A—polycystic ovary syndrome	0.000453	0.0961	CrCbGaD
Olanzapine—CHRM3—female gonad—polycystic ovary syndrome	0.000448	0.00724	CbGeAlD
Olanzapine—Quetiapine—ADRA1A—polycystic ovary syndrome	0.000442	0.0938	CrCbGaD
Olanzapine—ADRA1A—adrenal gland—polycystic ovary syndrome	0.000442	0.00713	CbGeAlD
Olanzapine—HRH1—endometrium—polycystic ovary syndrome	0.000423	0.00683	CbGeAlD
Olanzapine—ADRA2C—adrenal gland—polycystic ovary syndrome	0.000421	0.0068	CbGeAlD
Olanzapine—CHRM3—endocrine gland—polycystic ovary syndrome	0.000417	0.00674	CbGeAlD
Olanzapine—HTR1A—endocrine gland—polycystic ovary syndrome	0.000415	0.00671	CbGeAlD
Olanzapine—ADRA2A—endometrium—polycystic ovary syndrome	0.000415	0.00671	CbGeAlD
Olanzapine—CYP2C19—vagina—polycystic ovary syndrome	0.000414	0.00669	CbGeAlD
Olanzapine—HTR7—endocrine gland—polycystic ovary syndrome	0.000397	0.00641	CbGeAlD
Olanzapine—ADRA2C—female gonad—polycystic ovary syndrome	0.000392	0.00634	CbGeAlD
Olanzapine—ADRA2C—vagina—polycystic ovary syndrome	0.00039	0.0063	CbGeAlD
Olanzapine—CYP2C19—endocrine gland—polycystic ovary syndrome	0.000388	0.00626	CbGeAlD
Olanzapine—ADRA1A—endocrine gland—polycystic ovary syndrome	0.000383	0.00618	CbGeAlD
Olanzapine—ADRA2A—uterus—polycystic ovary syndrome	0.000383	0.00618	CbGeAlD
Olanzapine—HRH1—adipose tissue—polycystic ovary syndrome	0.000381	0.00615	CbGeAlD
Olanzapine—Clozapine—ADRA1A—polycystic ovary syndrome	0.00038	0.0807	CrCbGaD
Olanzapine—ADRA2A—pituitary gland—polycystic ovary syndrome	0.000376	0.00607	CbGeAlD
Olanzapine—DRD2—endocrine gland—polycystic ovary syndrome	0.000375	0.00606	CbGeAlD
Olanzapine—ADRA2A—adipose tissue—polycystic ovary syndrome	0.000374	0.00604	CbGeAlD
Olanzapine—HRH1—adrenal gland—polycystic ovary syndrome	0.000342	0.00552	CbGeAlD
Olanzapine—ADRA2A—adrenal gland—polycystic ovary syndrome	0.000336	0.00542	CbGeAlD
Olanzapine—HTR2A—pituitary gland—polycystic ovary syndrome	0.00032	0.00516	CbGeAlD
Olanzapine—HRH1—female gonad—polycystic ovary syndrome	0.000319	0.00515	CbGeAlD
Olanzapine—HRH1—vagina—polycystic ovary syndrome	0.000317	0.00512	CbGeAlD
Olanzapine—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000317	0.00511	CbGeAlD
Olanzapine—ABCB1—embryo—polycystic ovary syndrome	0.000316	0.00511	CbGeAlD
Olanzapine—ADRA2A—female gonad—polycystic ovary syndrome	0.000313	0.00506	CbGeAlD
Olanzapine—ADRA2A—vagina—polycystic ovary syndrome	0.000311	0.00503	CbGeAlD
Olanzapine—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000301	0.00485	CbGeAlD
Olanzapine—HRH1—endocrine gland—polycystic ovary syndrome	0.000296	0.00479	CbGeAlD
Olanzapine—ADRA2A—endocrine gland—polycystic ovary syndrome	0.000291	0.0047	CbGeAlD
Olanzapine—HTR2A—adrenal gland—polycystic ovary syndrome	0.000285	0.00461	CbGeAlD
Olanzapine—HTR2A—vagina—polycystic ovary syndrome	0.000265	0.00427	CbGeAlD
Olanzapine—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000259	0.00419	CbGeAlD
Olanzapine—HTR2A—endocrine gland—polycystic ovary syndrome	0.000248	0.004	CbGeAlD
Olanzapine—CYP2D6—female gonad—polycystic ovary syndrome	0.000243	0.00392	CbGeAlD
Olanzapine—ABCB1—endometrium—polycystic ovary syndrome	0.000231	0.00374	CbGeAlD
Olanzapine—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000229	0.0037	CbGeAlD
Olanzapine—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000226	0.00364	CbGeAlD
Olanzapine—ABCB1—uterus—polycystic ovary syndrome	0.000213	0.00344	CbGeAlD
Olanzapine—ABCB1—pituitary gland—polycystic ovary syndrome	0.000209	0.00338	CbGeAlD
Olanzapine—ABCB1—adipose tissue—polycystic ovary syndrome	0.000209	0.00337	CbGeAlD
Olanzapine—Clozapine—CYP1A1—polycystic ovary syndrome	0.000194	0.0411	CrCbGaD
Olanzapine—ABCB1—adrenal gland—polycystic ovary syndrome	0.000187	0.00302	CbGeAlD
Olanzapine—ABCB1—female gonad—polycystic ovary syndrome	0.000174	0.00282	CbGeAlD
Olanzapine—ABCB1—vagina—polycystic ovary syndrome	0.000173	0.0028	CbGeAlD
Olanzapine—ABCB1—endocrine gland—polycystic ovary syndrome	0.000162	0.00262	CbGeAlD
Olanzapine—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	3.04e-06	1.3e-05	CbGpPWpGaD
Olanzapine—HRH2—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.04e-06	1.3e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—TH—polycystic ovary syndrome	3.04e-06	1.3e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—IGF1—polycystic ovary syndrome	3.03e-06	1.3e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—AKT2—polycystic ovary syndrome	3.03e-06	1.3e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—GNAS—polycystic ovary syndrome	3.03e-06	1.3e-05	CbGpPWpGaD
Olanzapine—DRD5—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.02e-06	1.29e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	3e-06	1.28e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	3e-06	1.28e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	2.98e-06	1.27e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	2.97e-06	1.27e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	2.96e-06	1.26e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	2.95e-06	1.26e-05	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.92e-06	1.25e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—NCOR1—polycystic ovary syndrome	2.88e-06	1.23e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.88e-06	1.23e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	2.87e-06	1.23e-05	CbGpPWpGaD
Olanzapine—CHRM3—Metabolism—PPARG—polycystic ovary syndrome	2.85e-06	1.22e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.85e-06	1.22e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	2.85e-06	1.22e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	2.84e-06	1.21e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	2.83e-06	1.21e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	2.82e-06	1.21e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—IRS2—polycystic ovary syndrome	2.82e-06	1.21e-05	CbGpPWpGaD
Olanzapine—CHRM3—Metabolism—POMC—polycystic ovary syndrome	2.81e-06	1.2e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	2.81e-06	1.2e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—IRS2—polycystic ovary syndrome	2.81e-06	1.2e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	2.81e-06	1.2e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	2.8e-06	1.2e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—IRS2—polycystic ovary syndrome	2.8e-06	1.2e-05	CbGpPWpGaD
Olanzapine—CHRM3—Metabolism—INS—polycystic ovary syndrome	2.8e-06	1.2e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	2.78e-06	1.19e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—IRS2—polycystic ovary syndrome	2.77e-06	1.19e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	2.76e-06	1.18e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	2.76e-06	1.18e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	2.76e-06	1.18e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—LEP—polycystic ovary syndrome	2.76e-06	1.18e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—LEP—polycystic ovary syndrome	2.75e-06	1.18e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	2.75e-06	1.18e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—LEP—polycystic ovary syndrome	2.74e-06	1.17e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	2.74e-06	1.17e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	2.74e-06	1.17e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—CYP1A1—polycystic ovary syndrome	2.73e-06	1.17e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	2.73e-06	1.17e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	2.73e-06	1.17e-05	CbGpPWpGaD
Olanzapine—HTR6—Signaling by GPCR—IL6—polycystic ovary syndrome	2.73e-06	1.17e-05	CbGpPWpGaD
Olanzapine—HTR7—Signaling by GPCR—IL6—polycystic ovary syndrome	2.73e-06	1.17e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	2.72e-06	1.16e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	2.72e-06	1.16e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	2.72e-06	1.16e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—IRS1—polycystic ovary syndrome	2.72e-06	1.16e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—LEP—polycystic ovary syndrome	2.71e-06	1.16e-05	CbGpPWpGaD
Olanzapine—HRH4—Signaling Pathways—IL6—polycystic ovary syndrome	2.71e-06	1.16e-05	CbGpPWpGaD
Olanzapine—HTR1D—Signaling by GPCR—IL6—polycystic ovary syndrome	2.71e-06	1.16e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	2.71e-06	1.16e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	2.66e-06	1.14e-05	CbGpPWpGaD
Olanzapine—HTR1B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.65e-06	1.13e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	2.65e-06	1.13e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	2.64e-06	1.13e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.64e-06	1.13e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.64e-06	1.13e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	2.63e-06	1.12e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	2.63e-06	1.12e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	2.62e-06	1.12e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	2.62e-06	1.12e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—POMC—polycystic ovary syndrome	2.62e-06	1.12e-05	CbGpPWpGaD
Olanzapine—DRD4—Signaling by GPCR—IL6—polycystic ovary syndrome	2.61e-06	1.12e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—INS—polycystic ovary syndrome	2.6e-06	1.11e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.6e-06	1.11e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—TH—polycystic ovary syndrome	2.59e-06	1.11e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	2.59e-06	1.11e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	2.58e-06	1.1e-05	CbGpPWpGaD
Olanzapine—CHRM4—Signaling by GPCR—IL6—polycystic ovary syndrome	2.58e-06	1.1e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	2.57e-06	1.1e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Metabolism—INS—polycystic ovary syndrome	2.57e-06	1.1e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	2.56e-06	1.09e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	2.56e-06	1.09e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—MTHFR—polycystic ovary syndrome	2.55e-06	1.09e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	2.53e-06	1.08e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	2.52e-06	1.08e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	2.52e-06	1.08e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—IGF1—polycystic ovary syndrome	2.52e-06	1.08e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—AKT2—polycystic ovary syndrome	2.52e-06	1.08e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	2.51e-06	1.08e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.51e-06	1.07e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.51e-06	1.07e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	2.5e-06	1.07e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.5e-06	1.07e-05	CbGpPWpGaD
Olanzapine—HTR2B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.49e-06	1.07e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	2.49e-06	1.06e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	2.48e-06	1.06e-05	CbGpPWpGaD
Olanzapine—CHRM5—Signaling by GPCR—IL6—polycystic ovary syndrome	2.47e-06	1.06e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.47e-06	1.05e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.46e-06	1.05e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	2.45e-06	1.05e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.45e-06	1.05e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—IRS1—polycystic ovary syndrome	2.44e-06	1.05e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.43e-06	1.04e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.42e-06	1.04e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.41e-06	1.03e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	2.41e-06	1.03e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	2.4e-06	1.03e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	2.4e-06	1.02e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.39e-06	1.02e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	2.38e-06	1.02e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.37e-06	1.02e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	2.37e-06	1.01e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—POMC—polycystic ovary syndrome	2.37e-06	1.01e-05	CbGpPWpGaD
Olanzapine—HTR1E—Signaling Pathways—IL6—polycystic ovary syndrome	2.36e-06	1.01e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—POMC—polycystic ovary syndrome	2.36e-06	1.01e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	2.36e-06	1.01e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	2.36e-06	1.01e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—INS—polycystic ovary syndrome	2.36e-06	1.01e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—POMC—polycystic ovary syndrome	2.35e-06	1.01e-05	CbGpPWpGaD
Olanzapine—DRD1—Signaling by GPCR—IL6—polycystic ovary syndrome	2.35e-06	1.01e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	2.35e-06	1.01e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—INS—polycystic ovary syndrome	2.35e-06	1e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—INS—polycystic ovary syndrome	2.34e-06	1e-05	CbGpPWpGaD
Olanzapine—HTR6—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.33e-06	9.98e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—POMC—polycystic ovary syndrome	2.33e-06	9.97e-06	CbGpPWpGaD
Olanzapine—HTR7—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.33e-06	9.97e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	2.32e-06	9.94e-06	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.32e-06	9.93e-06	CbGpPWpGaD
Olanzapine—DRD3—Signaling by GPCR—IL6—polycystic ovary syndrome	2.32e-06	9.92e-06	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.32e-06	9.92e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—INS—polycystic ovary syndrome	2.32e-06	9.91e-06	CbGpPWpGaD
Olanzapine—HTR1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.31e-06	9.9e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	2.31e-06	9.9e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	2.31e-06	9.89e-06	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	2.29e-06	9.79e-06	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.28e-06	9.77e-06	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.28e-06	9.76e-06	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.28e-06	9.75e-06	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.28e-06	9.74e-06	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.27e-06	9.72e-06	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.27e-06	9.71e-06	CbGpPWpGaD
Olanzapine—HTR1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.27e-06	9.69e-06	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—IGF1—polycystic ovary syndrome	2.26e-06	9.68e-06	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—AKT2—polycystic ovary syndrome	2.26e-06	9.68e-06	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	2.26e-06	9.66e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.24e-06	9.59e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.24e-06	9.59e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.24e-06	9.58e-06	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	2.24e-06	9.57e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.24e-06	9.56e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.23e-06	9.56e-06	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	2.23e-06	9.55e-06	CbGpPWpGaD
Olanzapine—DRD4—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.23e-06	9.54e-06	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.2e-06	9.43e-06	CbGpPWpGaD
Olanzapine—CHRM4—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.2e-06	9.41e-06	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.17e-06	9.28e-06	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.16e-06	9.26e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.16e-06	9.24e-06	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.16e-06	9.23e-06	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.15e-06	9.2e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	2.15e-06	9.19e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.13e-06	9.11e-06	CbGpPWpGaD
Olanzapine—HTR2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.13e-06	9.11e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.12e-06	9.08e-06	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	2.12e-06	9.06e-06	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.11e-06	9.01e-06	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	2.1e-06	9e-06	CbGpPWpGaD
Olanzapine—HRH2—Signaling Pathways—IL6—polycystic ovary syndrome	2.1e-06	9e-06	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.09e-06	8.96e-06	CbGpPWpGaD
Olanzapine—DRD5—Signaling Pathways—IL6—polycystic ovary syndrome	2.09e-06	8.94e-06	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	2.09e-06	8.92e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.08e-06	8.89e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.08e-06	8.88e-06	CbGpPWpGaD
Olanzapine—ALB—Metabolism—PPARG—polycystic ovary syndrome	2.07e-06	8.84e-06	CbGpPWpGaD
Olanzapine—ALB—Metabolism—POMC—polycystic ovary syndrome	2.04e-06	8.72e-06	CbGpPWpGaD
Olanzapine—ALB—Metabolism—INS—polycystic ovary syndrome	2.03e-06	8.67e-06	CbGpPWpGaD
Olanzapine—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.02e-06	8.65e-06	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	2.02e-06	8.63e-06	CbGpPWpGaD
Olanzapine—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	2.01e-06	8.6e-06	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.01e-06	8.59e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—TH—polycystic ovary syndrome	2e-06	8.56e-06	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.98e-06	8.47e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.97e-06	8.44e-06	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	1.96e-06	8.37e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.95e-06	8.33e-06	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling by GPCR—IL6—polycystic ovary syndrome	1.92e-06	8.23e-06	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	1.91e-06	8.18e-06	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	1.86e-06	7.94e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.83e-06	7.83e-06	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	1.83e-06	7.83e-06	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—INS—polycystic ovary syndrome	1.82e-06	7.78e-06	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	1.81e-06	7.75e-06	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.79e-06	7.65e-06	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—POMC—polycystic ovary syndrome	1.79e-06	7.64e-06	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	1.78e-06	7.63e-06	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—INS—polycystic ovary syndrome	1.78e-06	7.6e-06	CbGpPWpGaD
Olanzapine—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.77e-06	7.59e-06	CbGpPWpGaD
Olanzapine—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.75e-06	7.47e-06	CbGpPWpGaD
Olanzapine—HRH1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.74e-06	7.45e-06	CbGpPWpGaD
Olanzapine—CHRM1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.74e-06	7.43e-06	CbGpPWpGaD
Olanzapine—CHRM3—Signaling by GPCR—IL6—polycystic ovary syndrome	1.73e-06	7.41e-06	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.73e-06	7.38e-06	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.72e-06	7.35e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.71e-06	7.33e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.71e-06	7.31e-06	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	1.71e-06	7.3e-06	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	1.69e-06	7.24e-06	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	1.68e-06	7.2e-06	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—INS—polycystic ovary syndrome	1.67e-06	7.16e-06	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.67e-06	7.15e-06	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	1.67e-06	7.14e-06	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—INS—polycystic ovary syndrome	1.66e-06	7.1e-06	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.64e-06	7.03e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.63e-06	6.99e-06	CbGpPWpGaD
Olanzapine—HTR6—Signaling Pathways—IL6—polycystic ovary syndrome	1.61e-06	6.9e-06	CbGpPWpGaD
Olanzapine—HTR7—Signaling Pathways—IL6—polycystic ovary syndrome	1.61e-06	6.89e-06	CbGpPWpGaD
Olanzapine—HTR1D—Signaling Pathways—IL6—polycystic ovary syndrome	1.6e-06	6.85e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.59e-06	6.8e-06	CbGpPWpGaD
Olanzapine—HTR1B—Signaling Pathways—IL6—polycystic ovary syndrome	1.57e-06	6.7e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.56e-06	6.66e-06	CbGpPWpGaD
Olanzapine—DRD4—Signaling Pathways—IL6—polycystic ovary syndrome	1.54e-06	6.6e-06	CbGpPWpGaD
Olanzapine—CHRM4—Signaling Pathways—IL6—polycystic ovary syndrome	1.52e-06	6.51e-06	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.52e-06	6.48e-06	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.49e-06	6.38e-06	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.49e-06	6.37e-06	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.48e-06	6.35e-06	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.48e-06	6.33e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.48e-06	6.31e-06	CbGpPWpGaD
Olanzapine—HTR2B—Signaling Pathways—IL6—polycystic ovary syndrome	1.47e-06	6.3e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.46e-06	6.26e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.46e-06	6.25e-06	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—IL6—polycystic ovary syndrome	1.46e-06	6.23e-06	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	1.45e-06	6.18e-06	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	1.43e-06	6.1e-06	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—INS—polycystic ovary syndrome	1.42e-06	6.07e-06	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—IL6—polycystic ovary syndrome	1.39e-06	5.94e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.38e-06	5.89e-06	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—IL6—polycystic ovary syndrome	1.37e-06	5.86e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.36e-06	5.8e-06	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	1.24e-06	5.29e-06	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.19e-06	5.11e-06	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.19e-06	5.08e-06	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.16e-06	4.94e-06	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—IL6—polycystic ovary syndrome	1.14e-06	4.86e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.12e-06	4.77e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.1e-06	4.71e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.09e-06	4.68e-06	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	1.05e-06	4.48e-06	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.03e-06	4.41e-06	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—IL6—polycystic ovary syndrome	1.03e-06	4.4e-06	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—IL6—polycystic ovary syndrome	1.03e-06	4.39e-06	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—IL6—polycystic ovary syndrome	1.02e-06	4.37e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—IL6—polycystic ovary syndrome	1.01e-06	4.33e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.01e-06	4.32e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	9.38e-07	4.01e-06	CbGpPWpGaD
